Targeting the glucocorticoid receptor-CCR8 axis mediated bone marrow T cell sequestration enhances infiltration of anti-tumor T cells in intracranial cancers.

in Cellular & molecular immunology by Jia Zhang, Yuzhu Shi, Xiaotong Xue, Wenqing Bu, Yanan Li, Tingting Yang, Lijuan Cao, Jiankai Fang, Peishan Li, Yongjing Chen, Zhen Li, Changshun Shao, Yufang Shi

TLDR

  • The study found that brain tumors make it harder for the body's immune system to fight them. The study looked at how this happens and found that it's because the body's immune system is being suppressed and the immune cells are being trapped in the bone marrow. The study also found that a specific type of immune cell called T cells are being affected by this. The study suggests that targeting a specific protein called CCR8 on these T cells could help the immune system fight the brain tumors better.

Abstract

Brain tumors such as glioblastomas are resistant to immune checkpoint blockade therapy, largely due to limited T cell infiltration in the tumors. Here, we show that mice bearing intracranial tumors exhibit systemic immunosuppression and T cell sequestration in bone marrow, leading to reduced T cell infiltration in brain tumors. Elevated plasma corticosterone drives the T cell sequestration via glucocorticoid receptors in tumor-bearing mice. Immunosuppression mediated by glucocorticoid-induced T cell dynamics and the subsequent tumor growth promotion can be abrogated by adrenalectomy, the administration of glucocorticoid activation inhibitors or glucocorticoid receptor antagonists, and in mice with T cell-specific deletion of glucocorticoid receptor. CCR8 expression in T cells is increased in tumor-bearing mice in a glucocorticoid receptor-dependent manner. Additionally, chemokines CCL1 and CCL8, the ligands for CCR8, are highly expressed in bone marrow immune cells in tumor-bearing mice to recruit T cells. These findings suggested that brain tumor-induced glucocorticoid surge and CCR8 upregulation in T cells lead to T cell sequestration in bone marrow, impairing the anti-tumor immune response. Targeting the glucocorticoid receptor-CCR8 axis may offer a promising immunotherapeutic approach for the treatment of intracranial tumors.

Overview

  • The study investigates the limited T cell infiltration in glioblastomas and its role in resistance to immune checkpoint blockade therapy. The study uses mice bearing intracranial tumors and shows that systemic immunosuppression and T cell sequestration in bone marrow lead to reduced T cell infiltration in brain tumors. The primary objective of the study is to understand the mechanisms underlying T cell sequestration in brain tumors and to identify potential immunotherapeutic targets for the treatment of glioblastomas.

Comparative Analysis & Findings

  • The study compares the outcomes observed under different experimental conditions, including adrenalectomy, glucocorticoid activation inhibitors, glucocorticoid receptor antagonists, and T cell-specific deletion of glucocorticoid receptor. The results show that these interventions can abrogate the immunosuppression mediated by glucocorticoid-induced T cell dynamics and the subsequent tumor growth promotion. The study identifies CCR8 expression in T cells as a key finding, which is increased in tumor-bearing mice in a glucocorticoid receptor-dependent manner. The chemokines CCL1 and CCL8, the ligands for CCR8, are also highly expressed in bone marrow immune cells in tumor-bearing mice to recruit T cells. These findings suggest that brain tumor-induced glucocorticoid surge and CCR8 upregulation in T cells lead to T cell sequestration in bone marrow, impairing the anti-tumor immune response.

Implications and Future Directions

  • The study's findings have significant implications for the field of research and clinical practice, as they suggest that targeting the glucocorticoid receptor-CCR8 axis may offer a promising immunotherapeutic approach for the treatment of glioblastomas. The study identifies several limitations, including the use of mice as a model system and the need for further validation in human studies. Future research directions could include the development of novel immunotherapeutic agents targeting the glucocorticoid receptor-CCR8 axis, as well as the exploration of other mechanisms underlying T cell sequestration in brain tumors.